{"id":76804,"date":"2026-11-03T19:41:31","date_gmt":"2026-11-03T19:41:31","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=76804"},"modified":"2026-11-03T19:41:31","modified_gmt":"2026-11-03T19:41:31","slug":"american-analyst-updates-nov-3rd-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/","title":{"rendered":"American Analyst Updates: Nov 3rd, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/strong><\/a><\/h2>\n

Analysts raised more price targets than they cut on Nov 3rd, but sentiment varied across sectors. Healthcare drew some of the strongest upward revisions, particularly in select biotech and medical technology names. Technology was split, with target increases for some enterprise software stocks and repeated cuts across semiconductors, chip equipment and optical components. Financials showed pockets of strength in insurance brokerage and regional banks, while consumer coverage was mixed, with target increases in beauty, household products and lodging alongside cuts in auto retail. Energy and housing showed more caution, with downgrades in oil and gas and weaker calls on homebuilders and real estate platforms.<\/p>\n

Updates (426)<\/strong><\/h3>\n

Adeia (ADEA)<\/strong> \u2014 Rosenblatt Securities lowered its price target to $35.00 from $40.00 and listed a Buy rating.<\/p>\n

Adidas AG (ADDYY)<\/strong> \u2014 UBS downgraded the stock to Sell from Neutral.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 Citigroup lowered its price target to $450.00 from $460.00 and listed a Buy rating.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 Morgan Stanley lowered its price target to $368.00 from $375.00 and listed a Overweight rating.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 Robert W. Baird lowered its price target to $330.00 from $410.00 and listed a Outperform rating.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 TD Cowen lowered its price target to $275.00 from $370.00 and listed a Hold rating.<\/p>\n

Advanced Energy Industries (AEIS)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $310.00 from $360.00 and listed a Overweight rating.<\/p>\n

Afya (AFYA)<\/strong> \u2014 Citigroup upgraded the stock to Buy from Neutral with a $12 price target.<\/p>\n

Afya (AFYA)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $17.50 from $19.00 and listed a Overweight rating.<\/p>\n

Airbnb (ABNB)<\/strong> \u2014 Raymond James Financial reiterated its Outperform rating.<\/p>\n

Airbnb (ABNB)<\/strong> \u2014 UBS Group raised its price target to $181.00 from $172.00 and listed a Neutral rating.<\/p>\n

AIRO Group Holdings (AIRO)<\/strong> \u2014 Roth Capital initiated coverage with a Buy rating and a $16 price target.<\/p>\n

Alexandria Real Estate Equities (ARE)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $47.00 from $51.00 and listed a Sector Perform rating.<\/p>\n

Allegion (ALLE)<\/strong> \u2014 Morgan Stanley raised its price target to $181.00 from $170.00 and listed a Equal Weight rating.<\/p>\n

Alpine Income Property Trust (PINE)<\/strong> \u2014 Truist Financial lowered its price target to $17.00 from $19.00 and listed a Hold rating.<\/p>\n

American Electric Power (AEP)<\/strong> \u2014 Jefferies Financial Group set its price target to $153.00.<\/p>\n

Aon (AON)<\/strong> \u2014 BMO Capital Markets upgraded the stock to Outperform from Market Perform with a $380 price target.<\/p>\n

Appian (APPN)<\/strong> \u2014 TD Cowen raised its price target to $50.00 from $30.00 and listed a Hold rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Argus raised its price target to $400.00 from $375.00 and listed a Buy rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Barclays raised its price target to $261.00 from $245.00 and listed a Underweight rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 DA Davidson raised its price target to $295.00 from $270.00 and listed a Neutral rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Guggenheim set its price target to $400.00.<\/p>\n

Apple (AAPL)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $355.00 from $360.00 and listed a Overweight rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 KeyCorp reiterated its Underweight rating with a $250.00 price target.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Melius Research set its price target to $370.00.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Morgan Stanley set its price target to $350.00 from $355.00 and listed a Overweight rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Raymond James Financial reiterated its Market Perform rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Robert W. Baird set its price target to $340.00 from $330.00 and listed a Outperform rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 Rosenblatt Securities reiterated its Neutral rating with a $303.00 price target.<\/p>\n

Apple (AAPL)<\/strong> \u2014 TD Cowen lowered its price target to $390.00 from $400.00 and listed a Buy rating.<\/p>\n

Apple (AAPL)<\/strong> \u2014 UBS Group set its price target to $370.00.<\/p>\n

Apple (AAPL)<\/strong> \u2014 UBS Group reiterated its Neutral rating with a $340.00 price target.<\/p>\n

Applied Materials (AMAT)<\/strong> \u2014 Morgan Stanley lowered its price target to $538.00 from $563.00 and listed a Equal Weight rating.<\/p>\n

Arthur J. Gallagher (AJG)<\/strong> \u2014 BMO Capital Markets downgraded the stock to Market Perform from Outperform with a $295 price target.<\/p>\n

Arvinas (ARVN)<\/strong> \u2014 HC Wainwright lowered its price target to $13.00 from $18.00 and listed a Buy rating.<\/p>\n

Assembly Biosciences (ASMB)<\/strong> \u2014 UBS Group lowered its price target to $48.00 from $52.00 and listed a Buy rating.<\/p>\n

Associated Banc (ASB)<\/strong> \u2014 Barclays raised its price target to $37.00 from $35.00 and listed a Overweight rating.<\/p>\n

Atlassian (TEAM)<\/strong> \u2014 TD Cowen raised its price target to $180.00 from $145.00 and listed a Hold rating.<\/p>\n

AutoNation (AN)<\/strong> \u2014 Barclays lowered its price target to $220.00 from $230.00 and listed a Overweight rating.<\/p>\n

AutoNation (AN)<\/strong> \u2014 Citigroup lowered its price target to $240.00 from $255.00 and listed a Buy rating.<\/p>\n

AvePoint (AVPT)<\/strong> \u2014 TD Cowen raised its price target to $18.00 from $15.00 and listed a Buy rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 Guggenheim lowered its price target to $250.00 from $275.00 and listed a Buy rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 Morgan Stanley raised its price target to $249.00 from $247.00 and listed a Equal Weight rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 Robert W. Baird lowered its price target to $220.00 from $246.00 and listed a Outperform rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $273.00 from $295.00 and listed a Outperform rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 UBS Group lowered its price target to $239.00 from $256.00 and listed a Buy rating.<\/p>\n

Axsome Therapeutics (AXSM)<\/strong> \u2014 Wells Fargo & Company reiterated its Outperform rating.<\/p>\n

Backblaze (BLZE)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Backblaze (BLZE)<\/strong> \u2014 Needham & Company LLC lowered its price target to $15.00 from $23.00 and listed a Buy rating.<\/p>\n

Bancorp (TBBK)<\/strong> \u2014 Raymond James Financial reiterated its Outperform rating with a $57.00 price target.<\/p>\n

Biohaven (BHVN)<\/strong> \u2014 Morgan Stanley raised its price target to $21.00 from $19.00 and listed a Overweight rating.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 HC Wainwright reiterated its Neutral rating with a $60.00 price target.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Morgan Stanley lowered its price target to $119.00 from $122.00 and listed a Overweight rating.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Oppenheimer lowered its price target to $94.00 from $97.00 and listed a Outperform rating.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $60.00 from $62.00 and listed a Sector Perform rating.<\/p>\n

BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Stifel Nicolaus lowered its price target to $66.00 from $70.00 and listed a Hold rating.<\/p>\n

Bioventus (BVS)<\/strong> \u2014 Canaccord Genuity Group lowered its price target to $18.00 from $19.00 and listed a Buy rating.<\/p>\n

Blackstone Mortgage Trust (BXMT)<\/strong> \u2014 UBS Group lowered its price target to $14.00 from $21.00 and listed a Buy rating.<\/p>\n

Block (XYZ)<\/strong> \u2014 BMO Capital Markets reiterated its Hold rating.<\/p>\n

Block (XYZ)<\/strong> \u2014 Citigroup upgraded the stock to Outperform from Buy.<\/p>\n

Bloom Energy (BE)<\/strong> \u2014 Barclays upgraded the stock to Overweight from Equal Weight with a $289 price target.<\/p>\n

Bloom Energy (BE)<\/strong> \u2014 BMO Capital Markets downgraded the stock to Market Perform from Outperform.<\/p>\n

Boise Cascade (BCC)<\/strong> \u2014 DA Davidson set its price target to $99.00.<\/p>\n

Booking (BKNG)<\/strong> \u2014 UBS Group lowered its price target to $265.00 from $274.00 and listed a Buy rating.<\/p>\n

Bright Minds Biosciences (DRUG)<\/strong> \u2014 Robert W. Baird lowered its price target to $107.00 from $126.00 and listed a Outperform rating.<\/p>\n

BrightSpring Health Services (BTSG)<\/strong> \u2014 Guggenheim raised its price target to $84.00 from $81.00 and listed a Buy rating.<\/p>\n

Cactus (WHD)<\/strong> \u2014 Citigroup raised its price target to $74.00 from $73.00 and listed a Neutral rating.<\/p>\n

Cactus (WHD)<\/strong> \u2014 Piper Sandler raised its price target to $78.00 from $75.00 and listed a Overweight rating.<\/p>\n

Canadian National Railway (CNI)<\/strong> \u2014 Susquehanna raised its price target to $140.00 from $130.00 and listed a Neutral rating.<\/p>\n

Canadian Pacific Kansas City (CP)<\/strong> \u2014 Susquehanna raised its price target to $105.00 from $98.00 and listed a Positive rating.<\/p>\n

Century Aluminum (CENX)<\/strong> \u2014 B. Riley Financial lowered its price target to $64.00 from $72.00 and listed a Buy rating.<\/p>\n

Charter Communications (CHTR)<\/strong> \u2014 Citigroup lowered its price target to $140.00 from $180.00 and listed a Buy rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Barclays raised its price target to $155.00 from $140.00 and listed a Equal Weight rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Cantor Fitzgerald reiterated its Neutral rating with a $150.00 price target.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Citigroup raised its price target to $145.00 from $130.00 and listed a Neutral rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $155.00 from $167.00 and listed a Neutral rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Morgan Stanley lowered its price target to $131.00 from $133.00 and listed a Equal Weight rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Robert W. Baird lowered its price target to $170.00 from $175.00 and listed a Outperform rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $140.00 from $135.00 and listed a Sector Perform rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Scotiabank lowered its price target to $175.00 from $185.00 and listed a Sector Outperform rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Susquehanna raised its price target to $165.00 from $150.00 and listed a Positive rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 UBS Group raised its price target to $150.00 from $145.00 and listed a Neutral rating.<\/p>\n

Check Point Software Technologies (CHKP)<\/strong> \u2014 Wells Fargo & Company raised its price target to $135.00 from $130.00 and listed a Equal Weight rating.<\/p>\n

Cheniere Energy (LNG)<\/strong> \u2014 Scotiabank raised its price target to $327.00 from $311.00 and listed a Sector Outperform rating.<\/p>\n

Cheniere Energy (LNG)<\/strong> \u2014 TD Cowen raised its price target to $352.00 from $325.00 and listed a Buy rating.<\/p>\n

Chevron (CVX)<\/strong> \u2014 DZ Bank downgraded the stock to Hold from Buy with a $240 price target.<\/p>\n

Choice Hotels International (CHH)<\/strong> \u2014 Barclays raised its price target to $107.00 from $103.00 and listed a Underweight rating.<\/p>\n

Church & Dwight (CHD)<\/strong> \u2014 Barclays raised its price target to $89.00 from $83.00 and listed a Underweight rating.<\/p>\n

Church & Dwight (CHD)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a $115.00 price target.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 Cantor Fitzgerald lowered its price target to $15.00 from $19.00 and listed a Overweight rating.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $18.00 from $22.00 and listed a Overweight rating.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 Needham & Company LLC lowered its price target to $15.00 from $25.00 and listed a Buy rating.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 Rosenblatt Securities lowered its price target to $19.00 from $30.00 and listed a Buy rating.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 UBS Group reiterated its Overweight rating with a $18.00 price target.<\/p>\n

Cipher Mining (CIFR)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $15.00 from $25.00 and listed a Overweight rating.<\/p>\n

Civeo (CVEO)<\/strong> \u2014 Stifel Nicolaus raised its price target to $42.00 from $37.00 and listed a Buy rating.<\/p>\n

Clorox (CLX)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Clorox (CLX)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $86.00 from $83.00 and listed a Underweight rating.<\/p>\n

Clorox (CLX)<\/strong> \u2014 TD Cowen reiterated its Hold rating.<\/p>\n

Clorox (CLX)<\/strong> \u2014 The Goldman Sachs Group reiterated its Sell rating with a $74.00 price target.<\/p>\n

Clorox (CLX)<\/strong> \u2014 UBS Group raised its price target to $96.00 from $91.00 and listed a Neutral rating.<\/p>\n

Clorox (CLX)<\/strong> \u2014 UBS Group set its price target to $88.00.<\/p>\n

Clorox (CLX)<\/strong> \u2014 Wells Fargo & Company raised its price target to $90.00 from $85.00 and listed a Equal Weight rating.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Craig Hallum upgraded the stock to Buy.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Fox Advisors downgraded the stock to Neutral.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 JPMorgan upgraded the stock to Overweight from Neutral with a $350 price target.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Morgan Stanley initiated coverage with a Overweight rating.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Oppenheimer initiated coverage with a Outperform rating.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Raymond James Financial downgraded the stock to Underperform from Strong-Buy.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Stephens initiated coverage with a Overweight rating.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 TD Cowen downgraded the stock to Hold from Buy.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 UBS Group initiated coverage with a Buy rating.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 Wedbush initiated coverage with a Outperform rating.<\/p>\n

Coca Cola FEMSA (KOF)<\/strong> \u2014 Barclays raised its price target to $125.00 from $122.00 and listed a Equal Weight rating.<\/p>\n

Coca Cola FEMSA (KOF)<\/strong> \u2014 Itau BBA Securities downgraded the stock to Market Perform from Outperform with a $116.00 price target.<\/p>\n

Coca-Cola FEMSA (KOF)<\/strong> \u2014 Itau BBA downgraded the stock to Market Perform from Outperform with a $116 price target.<\/p>\n

Coinbase Global (COIN)<\/strong> \u2014 Keefe, Bruyette & Woods lowered its price target to $221.00 from $237.00 and listed a Outperform rating.<\/p>\n

Colgate-Palmolive (CL)<\/strong> \u2014 Barclays raised its price target to $95.00 from $87.00 and listed a Equal Weight rating.<\/p>\n

Columbia Banking System (COLB)<\/strong> \u2014 Barclays raised its price target to $34.00 from $32.00 and listed a Equal Weight rating.<\/p>\n

Community Health Systems (CYH)<\/strong> \u2014 Truist Financial lowered its price target to $2.50 from $3.25 and listed a Hold rating.<\/p>\n

Community Health Systems (CYH)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $1.00 from $2.00 and listed a Underweight rating.<\/p>\n

Compass Pathways (CMPS)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a $25.00 price target.<\/p>\n

CRISPR Therapeutics (CRSP)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

CRISPR Therapeutics (CRSP)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a $82.00 price target.<\/p>\n

CSW Industrials (CSW)<\/strong> \u2014 Citigroup lowered its price target to $326.00 from $340.00 and listed a Neutral rating.<\/p>\n

D.R. Horton (DHI)<\/strong> \u2014 Morgan Stanley lowered its price target to $130.00 from $151.00 and listed a Equal Weight rating.<\/p>\n

D.R. Horton (DHI)<\/strong> \u2014 Raymond James downgraded the stock to Underperform from Market Perform.<\/p>\n

D.R. Horton (DHI)<\/strong> \u2014 Raymond James Financial downgraded the stock to Underperform from Market Perform.<\/p>\n

DraftKings (DKNG)<\/strong> \u2014 Sanford C. Bernstein lowered its price target to $27.00 from $29.00 and listed a Outperform rating.<\/p>\n

Dropbox (DBX)<\/strong> \u2014 Stephens initiated coverage with a Equal Weight rating and a $39 price target.<\/p>\n

DT Midstream (DTM)<\/strong> \u2014 Morgan Stanley lowered its price target to $161.00 from $164.00 and listed a Overweight rating.<\/p>\n

DT Midstream (DTM)<\/strong> \u2014 Scotiabank lowered its price target to $161.00 from $165.00 and listed a Sector Outperform rating.<\/p>\n

Dynatrace (DT)<\/strong> \u2014 BTIG Research lowered its price target to $63.00 from $73.00 and listed a Buy rating.<\/p>\n

Dynatrace (DT)<\/strong> \u2014 Needham & Company LLC lowered its price target to $65.00 from $68.00 and listed a Buy rating.<\/p>\n

East West Bancorp (EWBC)<\/strong> \u2014 Barclays raised its price target to $160.00 from $155.00 and listed a Overweight rating.<\/p>\n

Eastern Bankshares (EBC)<\/strong> \u2014 Barclays raised its price target to $24.00 from $23.00 and listed a Equal Weight rating.<\/p>\n

Eastman Chemical (EMN)<\/strong> \u2014 Citigroup lowered its price target to $75.00 from $76.00 and listed a Buy rating.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 Morgan Stanley lowered its price target to $140.00 from $145.00 and listed a Underweight rating.<\/p>\n

Entergy (ETR)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a $124.00 price target.<\/p>\n

Equity Lifestyle Properties (ELS)<\/strong> \u2014 Truist Financial lowered its price target to $63.00 from $64.00 and listed a Hold rating.<\/p>\n

Ero Copper (ERO)<\/strong> \u2014 Scotiabank upgraded the stock to Sector Outperform from Sector Perform.<\/p>\n

Essential Properties Realty Trust (EPRT)<\/strong> \u2014 Cantor Fitzgerald lowered its price target to $31.00 from $37.00 and listed a Overweight rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 Citigroup raised its price target to $121.00 from $115.00 and listed a Buy rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $120.00 from $115.00 and listed a Overweight rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 Morgan Stanley raised its price target to $118.00 from $112.00 and listed a Equal Weight rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $126.00 from $120.00 and listed a Outperform rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 UBS Group raised its price target to $112.00 from $104.00 and listed a Neutral rating.<\/p>\n

Estee Lauder Companies (EL)<\/strong> \u2014 Wells Fargo & Company raised its price target to $110.00 from $95.00 and listed a Equal Weight rating.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating with a $35.00 price target.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 Canaccord Genuity Group raised its price target to $32.00 from $28.00 and listed a Buy rating.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $30.00 from $29.00 and listed a Overweight rating.<\/p>\n

EverQuote (EVER)<\/strong> \u2014 Needham & Company LLC raised its price target to $35.00 from $30.00 and listed a Buy rating.<\/p>\n

EVgo (EVGO)<\/strong> \u2014 Cantor Fitzgerald downgraded the stock to Neutral from Overweight with a $2.00 price target.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 UBS Group lowered its price target to $328.00 from $351.00 and listed a Neutral rating.<\/p>\n

Exzeo Group (XZO)<\/strong> \u2014 Truist Financial reiterated its Buy rating with a $24.00 price target.<\/p>\n

Fabrinet (FN)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $470.00 from $465.00 and listed a Neutral rating.<\/p>\n

Fabrinet (FN)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a $500.00 price target.<\/p>\n

Fabrinet (FN)<\/strong> \u2014 Rosenblatt Securities lowered its price target to $600.00 from $750.00 and listed a Buy rating.<\/p>\n

Federated Hermes (FHI)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $63.00 from $60.00 and listed a Sector Perform rating.<\/p>\n

FedEx (FDX)<\/strong> \u2014 Raymond James Financial set its price target to $162.00.<\/p>\n

FIGS (FIGS)<\/strong> \u2014 Barclays raised its price target to $24.00 from $20.00 and listed a Overweight rating.<\/p>\n

Flagstar Bank, National Association (FLG)<\/strong> \u2014 Barclays lowered its price target to $13.00 from $14.00 and listed a Overweight rating.<\/p>\n

Fluence Energy (FLNC)<\/strong> \u2014 The Goldman Sachs Group lowered its price target to $7.00 from $9.00 and listed a Neutral rating.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Sanford C. Bernstein lowered its price target to $100.00 from $110.00 and listed a Market Perform rating.<\/p>\n

FMC (FMC)<\/strong> \u2014 Citigroup raised its price target to $7.00 from $6.00 and listed a Neutral rating.<\/p>\n

FMC (FMC)<\/strong> \u2014 UBS Group lowered its price target to $6.50 from $10.00 and listed a Neutral rating.<\/p>\n

Fomento Economico Mexicano (FMX)<\/strong> \u2014 Barclays raised its price target to $140.00 from $138.00 and listed a Equal Weight rating.<\/p>\n

FOX (FOXA)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $83.00 from $82.00 and listed a Overweight rating.<\/p>\n

GE HealthCare Technologies (GEHC)<\/strong> \u2014 UBS Group raised its price target to $80.00 from $73.00 and listed a Neutral rating.<\/p>\n

GE Vernova (GEV)<\/strong> \u2014 Argus lowered its price target to $1,100.00 from $1,300.00 and listed a Buy rating.<\/p>\n

General Dynamics (GD)<\/strong> \u2014 Morgan Stanley raised its price target to $480.00 from $465.00 and listed a Overweight rating.<\/p>\n

General Dynamics (GD)<\/strong> \u2014 Sanford C. Bernstein raised its price target to $386.00 from $365.00 and listed a Market Perform rating.<\/p>\n

General Fusion Group Ltd. (GFUZ)<\/strong> \u2014 Wedbush initiated coverage with a Neutral rating and a $7 price target.<\/p>\n

GFL Environmental (GFL)<\/strong> \u2014 Truist Financial lowered its price target to $55.00 from $60.00 and listed a Buy rating.<\/p>\n

Gildan Activewear (GIL)<\/strong> \u2014 Scotiabank reiterated its Sector Outperform rating with a $53.00 price target.<\/p>\n

Grab (GRAB)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $5.10 from $4.80 and listed a Overweight rating.<\/p>\n

Halozyme Therapeutics (HALO)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $79.00 from $78.00 and listed a Neutral rating.<\/p>\n

Harmonic (HLIT)<\/strong> \u2014 Barclays lowered its price target to $14.00 from $16.00 and listed a Equal Weight rating.<\/p>\n

HCA Healthcare (HCA)<\/strong> \u2014 Truist Financial reiterated its Buy rating with a $510.00 price target.<\/p>\n

HealthStream (HSTM)<\/strong> \u2014 Craig Hallum downgraded the stock to Hold from Buy with a $40 price target.<\/p>\n

Hilton Worldwide (HLT)<\/strong> \u2014 Citigroup raised its price target to $400.00 from $335.00 and listed a Neutral rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Canaccord Genuity Group raised its price target to $134.00 from $105.00 and listed a Buy rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Morgan Stanley raised its price target to $131.00 from $117.00 and listed a Overweight rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Needham & Company LLC raised its price target to $135.00 from $115.00 and listed a Buy rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $135.00 from $110.00 and listed a Outperform rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Stifel Nicolaus raised its price target to $135.00 from $130.00 and listed a Buy rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Truist Financial raised its price target to $145.00 from $112.00 and listed a Buy rating.<\/p>\n

Hinge Health (HNGE)<\/strong> \u2014 Wells Fargo & Company raised its price target to $132.00 from $103.00 and listed a Overweight rating.<\/p>\n

Hippo (HIPO)<\/strong> \u2014 Keefe, Bruyette & Woods raised its price target to $37.00 from $35.00 and listed a Market Perform rating.<\/p>\n

Howmet Aerospace (HWM)<\/strong> \u2014 KeyBanc Capital Markets upgraded the stock to Overweight from Sector Weight with a $237 price target.<\/p>\n

Huntington Ingalls Industries (HII)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $375.00 from $370.00 and listed a Neutral rating.<\/p>\n

Huntington Ingalls Industries (HII)<\/strong> \u2014 Sanford C. Bernstein raised its price target to $352.00 from $304.00 and listed a Market Perform rating.<\/p>\n

Ibotta (IBTA)<\/strong> \u2014 Evercore set its price target to $58.00.<\/p>\n

Ibotta (IBTA)<\/strong> \u2014 Goldman Sachs upgraded the stock to Neutral from Sell with a $58 price target.<\/p>\n

Ibotta (IBTA)<\/strong> \u2014 Needham & Company LLC raised its price target to $65.00 from $45.00 and listed a Buy rating.<\/p>\n

Ibotta (IBTA)<\/strong> \u2014 Wells Fargo & Company raised its price target to $49.00 from $40.00 and listed a Equal Weight rating.<\/p>\n

Ichor (ICHR)<\/strong> \u2014 B. Riley Financial lowered its price target to $70.00 from $85.00 and listed a Buy rating.<\/p>\n

Ichor (ICHR)<\/strong> \u2014 Needham & Company LLC lowered its price target to $55.00 from $88.00 and listed a Buy rating.<\/p>\n

Ichor (ICHR)<\/strong> \u2014 Stifel Nicolaus lowered its price target to $93.00 from $115.00 and listed a Buy rating.<\/p>\n

Ichor (ICHR)<\/strong> \u2014 TD Cowen lowered its price target to $55.00 from $100.00 and listed a Buy rating.<\/p>\n

IDACORP (IDA)<\/strong> \u2014 Barclays raised its price target to $163.00 from $149.00 and listed a Overweight rating.<\/p>\n

IDEXX Laboratories (IDXX)<\/strong> \u2014 Morgan Stanley raised its price target to $810.00 from $805.00 and listed a Overweight rating.<\/p>\n

IDEXX Laboratories (IDXX)<\/strong> \u2014 UBS Group raised its price target to $700.00 from $627.00 and listed a Neutral rating.<\/p>\n

Independent Bank (INDB)<\/strong> \u2014 Barclays raised its price target to $86.00 from $82.00 and listed a Underweight rating.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Barclays lowered its price target to $62.00 from $65.00 and listed a Underweight rating.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $65.00 from $60.00 and listed a Neutral rating.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Piper Sandler raised its price target to $70.00 from $60.00 and listed a Neutral rating.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Robert W. Baird raised its price target to $77.00 from $73.00 and listed a Neutral rating.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Truist Financial reiterated its Hold rating with a $76.00 price target.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Wells Fargo & Company raised its price target to $69.00 from $56.00 and listed a Equal Weight rating.<\/p>\n

Iovance Biotherapeutics (IOVA)<\/strong> \u2014 UBS Group raised its price target to $8.00 from $7.00 and listed a Neutral rating.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Barclays raised its price target to $275.00 from $271.00 and listed a Overweight rating.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $310.00 from $300.00 and listed a Overweight rating.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Morgan Stanley raised its price target to $319.00 from $314.00 and listed a Overweight rating.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $305.00 from $296.00 and listed a Outperform rating.<\/p>\n

Jersey Mike’s (JMKE)<\/strong> \u2014 Guggenheim lowered its price target to $28.00 from $29.00 and listed a Buy rating.<\/p>\n

KB Home (KBH)<\/strong> \u2014 Morgan Stanley lowered its price target to $37.00 from $39.00 and listed a Underweight rating.<\/p>\n

Kinder Morgan (KMI)<\/strong> \u2014 Morgan Stanley lowered its price target to $39.00 from $40.00 and listed a Equal Weight rating.<\/p>\n

KKR Real Estate Finance Trust (KREF)<\/strong> \u2014 Keefe, Bruyette & Woods lowered its price target to $5.50 from $6.50 and listed a Market Perform rating.<\/p>\n

Krystal Biotech (KRYS)<\/strong> \u2014 Citigroup lowered its price target to $412.00 from $416.00 and listed a Buy rating.<\/p>\n

Krystal Biotech (KRYS)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $375.00 from $400.00 and listed a Outperform rating.<\/p>\n

Krystal Biotech (KRYS)<\/strong> \u2014 TD Cowen lowered its price target to $380.00 from $403.00 and listed a Buy rating.<\/p>\n

L3Harris Technologies (LHX)<\/strong> \u2014 Bank of America raised its price target to $375.00 from $325.00 and listed a Buy rating.<\/p>\n

Lattice Semiconductor (LSCC)<\/strong> \u2014 Robert W. Baird set its price target to $195.00.<\/p>\n

Lattice Semiconductor (LSCC)<\/strong> \u2014 Rosenblatt Securities raised its price target to $200.00 from $175.00 and listed a Buy rating.<\/p>\n

Lattice Semiconductor (LSCC)<\/strong> \u2014 Stifel Nicolaus raised its price target to $175.00 from $165.00 and listed a Buy rating.<\/p>\n

Lennar (LEN)<\/strong> \u2014 Morgan Stanley lowered its price target to $58.00 from $65.00 and listed a Underweight rating.<\/p>\n

Lsb Industries (LXU)<\/strong> \u2014 UBS Group raised its price target to $12.50 from $12.00 and listed a Neutral rating.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 B. Riley Financial downgraded the stock to Neutral from Buy with a $770.00 price target.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 B. Riley Securities downgraded the stock to Neutral from Buy with a $770 price target.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 Needham & Company LLC lowered its price target to $800.00 from $1,040.00 and listed a Buy rating.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 Rosenblatt Securities lowered its price target to $900.00 from $1,300.00 and listed a Buy rating.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 Susquehanna lowered its price target to $950.00 from $1,100.00 and listed a Positive rating.<\/p>\n

Lumentum (LITE)<\/strong> \u2014 TD Cowen lowered its price target to $685.00 from $820.00 and listed a Hold rating.<\/p>\n

Lyell Immunopharma (LYEL)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a $44.00 price target.<\/p>\n

LyondellBasell Industries (LYB)<\/strong> \u2014 Citigroup raised its price target to $74.00 from $63.00 and listed a Neutral rating.<\/p>\n

LyondellBasell Industries (LYB)<\/strong> \u2014 UBS Group raised its price target to $69.00 from $62.00 and listed a Neutral rating.<\/p>\n

Madrigal Pharmaceuticals (MDGL)<\/strong> \u2014 Citigroup raised its price target to $760.00 from $725.00 and listed a Buy rating.<\/p>\n

ManpowerGroup (MAN)<\/strong> \u2014 BNP Paribas Exane downgraded the stock to Neutral from Outperform with a $52.50 price target.<\/p>\n

Marriott International (MAR)<\/strong> \u2014 Barclays raised its price target to $409.00 from $363.00 and listed a Equal Weight rating.<\/p>\n

Marriott International (MAR)<\/strong> \u2014 Robert W. Baird raised its price target to $414.00 from $395.00 and listed a Neutral rating.<\/p>\n

Marriott International (MAR)<\/strong> \u2014 The Goldman Sachs Group raised its price target to $456.00 from $406.00 and listed a Buy rating.<\/p>\n

Marriott International (MAR)<\/strong> \u2014 Wells Fargo & Company raised its price target to $463.00 from $426.00 and listed a Overweight rating.<\/p>\n

Marsh McLennan (MRSH)<\/strong> \u2014 BMO Capital Markets upgraded the stock to Outperform from Market Perform with a $230 price target.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 B. Riley Financial lowered its price target to $275.00 from $365.00 and listed a Buy rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 BofA Securities downgraded the stock to Neutral from Buy with a $225 price target.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Cantor Fitzgerald lowered its price target to $225.00 from $350.00 and listed a Neutral rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Needham & Company LLC lowered its price target to $300.00 from $400.00 and listed a Buy rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $250.00 from $425.00 and listed a Outperform rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Susquehanna lowered its price target to $300.00 from $340.00 and listed a Positive rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 TD Cowen downgraded the stock to Hold from Buy with a $175 price target.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 UBS Group reiterated its Buy rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $285.00 from $365.00 and listed a Overweight rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Barclays raised its price target to $52.00 from $51.00 and listed a Overweight rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Citigroup raised its price target to $45.00 from $39.00 and listed a Neutral rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Needham & Company LLC upgraded the stock to Buy.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Susquehanna raised its price target to $50.00 from $45.00 and listed a Positive rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Truist Financial raised its price target to $44.00 from $41.00 and listed a Hold rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 UBS Group raised its price target to $43.00 from $38.00 and listed a Neutral rating.<\/p>\n

Match Group (MTCH)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $38.00 from $39.00 and listed a Equal Weight rating.<\/p>\n

Mechanics Bancorp (MCHB)<\/strong> \u2014 Cantor Fitzgerald lowered its price target to $16.00 from $17.00 and listed a Overweight rating.<\/p>\n

Medical Properties Trust (MPT)<\/strong> \u2014 BNP Paribas Exane downgraded the stock to Neutral from Outperform with a $2.25 price target.<\/p>\n

Merck (MRK)<\/strong> \u2014 DZ Bank downgraded the stock to Hold from Buy with a $153 price target.<\/p>\n

Meridian Bank (MRBK)<\/strong> \u2014 DA Davidson downgraded the stock to Neutral from Buy with a $20 price target.<\/p>\n

Mistras Group (MG)<\/strong> \u2014 Roth Capital downgraded the stock to Neutral from Buy with a $20.35 price target.<\/p>\n

MNTN (MNTN)<\/strong> \u2014 Freedom Broker initiated coverage with a Buy rating and a $16.50 price target.<\/p>\n

monday.com (MNDY)<\/strong> \u2014 Guggenheim reiterated its Buy rating with a $130.00 price target.<\/p>\n

monday.com (MNDY)<\/strong> \u2014 Morgan Stanley set its price target to $105.00.<\/p>\n

Monday.com (MNDY)<\/strong> \u2014 TD Cowen downgraded the stock to Hold from Buy with a $105 price target.<\/p>\n

Nabors Industries (NBR)<\/strong> \u2014 Piper Sandler raised its price target to $145.00 from $130.00 and listed a Overweight rating.<\/p>\n

NANO Nuclear Energy (NNE)<\/strong> \u2014 Wedbush initiated coverage with a Outperform rating and a $18 price target.<\/p>\n

NAPCO Security Technologies (NSSC)<\/strong> \u2014 TD Cowen lowered its price target to $45.00 from $55.00 and listed a Buy rating.<\/p>\n

Neurocrine Biosciences (NBIX)<\/strong> \u2014 Canaccord Genuity Group raised its price target to $220.00 from $210.00 and listed a Buy rating.<\/p>\n

Neurocrine Biosciences (NBIX)<\/strong> \u2014 Morgan Stanley raised its price target to $185.00 from $183.00 and listed a Equal Weight rating.<\/p>\n

Neurocrine Biosciences (NBIX)<\/strong> \u2014 Piper Sandler raised its price target to $215.00 from $210.00 and listed a Overweight rating.<\/p>\n

Neurocrine Biosciences (NBIX)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $190.00 from $187.00 and listed a Outperform rating.<\/p>\n

Nextpower (NXT)<\/strong> \u2014 Glj Research raised its price target to $158.00 from $149.00 and listed a Buy rating.<\/p>\n

nLight (LASR)<\/strong> \u2014 Needham & Company LLC initiated coverage with a Buy rating and a $50.00 price target.<\/p>\n

NuScale Power (SMR)<\/strong> \u2014 Wedbush initiated coverage with a Underperform rating and a $5 price target.<\/p>\n

NVR (NVR)<\/strong> \u2014 Morgan Stanley lowered its price target to $4,864.00 from $5,058.00 and listed a Underweight rating.<\/p>\n

Oklo Inc. (OKLO)<\/strong> \u2014 Wedbush resumed coverage with a Outperform rating and a $36 price target.<\/p>\n

Olin (OLN)<\/strong> \u2014 Wells Fargo & Company raised its price target to $17.00 from $16.00 and listed a Equal Weight rating.<\/p>\n

ON (ONON)<\/strong> \u2014 BTIG Research reiterated its Buy rating with a $60.00 price target.<\/p>\n

ON (ONON)<\/strong> \u2014 Cantor Fitzgerald upgraded the stock to Buy.<\/p>\n

Once Upon a Farm (OFRM)<\/strong> \u2014 BofA Securities downgraded the stock to Underperform from Buy with a $10 price target.<\/p>\n

Once Upon A Farm (OFRM)<\/strong> \u2014 TD Cowen lowered its price target to $13.00 from $18.00 and listed a Hold rating.<\/p>\n

OneMain (OMF)<\/strong> \u2014 Truist Financial lowered its price target to $70.00 from $71.00 and listed a Buy rating.<\/p>\n

ONEOK (OKE)<\/strong> \u2014 Scotiabank raised its price target to $97.00 from $96.00 and listed a Sector Perform rating.<\/p>\n

onsemi (ON)<\/strong> \u2014 B. Riley Financial lowered its price target to $97.00 from $105.00 and listed a Buy rating.<\/p>\n

onsemi (ON)<\/strong> \u2014 Cantor Fitzgerald reiterated its Neutral rating with a $90.00 price target.<\/p>\n

onsemi (ON)<\/strong> \u2014 Craig Hallum upgraded the stock to Buy from Hold with a $85 price target.<\/p>\n

onsemi (ON)<\/strong> \u2014 DA Davidson set its price target to $110.00.<\/p>\n

onsemi (ON)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a $116.00 price target.<\/p>\n

onsemi (ON)<\/strong> \u2014 Rosenblatt Securities lowered its price target to $80.00 from $85.00 and listed a Neutral rating.<\/p>\n

onsemi (ON)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a $75.00 price target.<\/p>\n

onsemi (ON)<\/strong> \u2014 Truist Financial raised its price target to $76.00 from $75.00 and listed a Hold rating.<\/p>\n

onsemi (ON)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $90.00 from $100.00 and listed a Overweight rating.<\/p>\n

Oppenheimer (OPY)<\/strong> \u2014 Needham & Company LLC upgraded the stock to Outperform.<\/p>\n

Oshkosh (OSK)<\/strong> \u2014 Morgan Stanley lowered its price target to $139.00 from $147.00 and listed a Equal Weight rating.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Citigroup raised its price target to $265.00 from $250.00 and listed a Buy rating.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 DA Davidson reiterated its Buy rating with a $250.00 price target.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Morgan Stanley raised its price target to $233.00 from $205.00 and listed a Buy rating.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating with a $235.00 price target.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a $260.00 price target.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $130.00 from $90.00 and listed a Underperform rating.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 The Goldman Sachs Group reiterated its Buy rating with a $235.00 price target.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 Truist Financial reiterated its Buy rating with a $250.00 price target.<\/p>\n

Palantir Technologies (PLTR)<\/strong> \u2014 UBS Group reiterated its Buy rating.<\/p>\n

Patterson-UTI Energy (PTEN)<\/strong> \u2014 Piper Sandler raised its price target to $15.00 from $14.00 and listed a Overweight rating.<\/p>\n

Penske Automotive Group (PAG)<\/strong> \u2014 Barclays raised its price target to $212.00 from $210.00 and listed a Overweight rating.<\/p>\n

Philip Morris International (PM)<\/strong> \u2014 Stifel Nicolaus raised its price target to $232.00 from $205.00 and listed a Buy rating.<\/p>\n

Piper Sandler Companies (PIPR)<\/strong> \u2014 Bank of America reiterated its Underperform rating with a $69.00 price target.<\/p>\n

Pony AI (PONY)<\/strong> \u2014 Morgan Stanley initiated coverage with a Overweight rating and a $10 price target.<\/p>\n

Powerus (PUSA)<\/strong> \u2014 Northland Securities initiated coverage with a Outperform rating and a $5.00 price target.<\/p>\n

Powerus Corporation (PUSA)<\/strong> \u2014 Northland Capital initiated coverage with a Outperform rating and a $5 price target.<\/p>\n

Precision Drilling (PDS)<\/strong> \u2014 Piper Sandler raised its price target to $115.00 from $105.00 and listed a Overweight rating.<\/p>\n

Primis Financial (FRST)<\/strong> \u2014 Keefe, Bruyette & Woods lowered its price target to $17.00 from $18.00 and listed a Outperform rating.<\/p>\n

Protagonist Therapeutics (PTGX)<\/strong> \u2014 UBS Group reiterated its Buy rating.<\/p>\n

Public Service Enterprise Group (PEG)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $87.00 from $89.00 and listed a Overweight rating.<\/p>\n

PulteGroup (PHM)<\/strong> \u2014 Morgan Stanley lowered its price target to $120.00 from $128.00 and listed a Equal Weight rating.<\/p>\n

Realty Income (O)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $61.00 from $60.00 and listed a Outperform rating.<\/p>\n

Retension Pharmaceuticals (RTSN)<\/strong> \u2014 Oppenheimer initiated coverage with a Outperform rating and a $50.00 price target.<\/p>\n

Rexford Industrial Realty (REXR)<\/strong> \u2014 Truist Financial raised its price target to $42.00 from $39.00 and listed a Buy rating.<\/p>\n

Roku (ROKU)<\/strong> \u2014 BMO Capital Markets upgraded the stock to Outperform from Market Perform.<\/p>\n

Roku (ROKU)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating.<\/p>\n

Roku (ROKU)<\/strong> \u2014 Rosenblatt Securities downgraded the stock to Neutral from Buy with a $160.00 price target.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 Citigroup lowered its price target to $225.00 from $235.00 and listed a Buy rating.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $200.00 from $220.00 and listed a Neutral rating.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 TD Cowen raised its price target to $239.00 from $229.00 and listed a Buy rating.<\/p>\n

SBA Communications (SBAC)<\/strong> \u2014 Wells Fargo & Company set its price target to $200.00.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Argus reiterated its Buy rating with a $170.00 price target.<\/p>\n

SiBone (SIBN)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

SiBone (SIBN)<\/strong> \u2014 Needham & Company LLC lowered its price target to $26.00 from $27.00 and listed a Buy rating.<\/p>\n

SiBone (SIBN)<\/strong> \u2014 TD Cowen raised its price target to $23.00 from $20.00 and listed a Buy rating.<\/p>\n

SiBone (SIBN)<\/strong> \u2014 UBS Group raised its price target to $26.00 from $25.00 and listed a Buy rating.<\/p>\n

Sierra Bancorp (BSRR)<\/strong> \u2014 Keefe, Bruyette & Woods raised its price target to $44.00 from $42.00 and listed a Market Perform rating.<\/p>\n

Sirius XM (SIRI)<\/strong> \u2014 Goldman Sachs upgraded the stock to Buy from Neutral with a $37 price target.<\/p>\n

Sirius XM (SIRI)<\/strong> \u2014 JPMorgan Chase & Co. lowered its price target to $32.00 from $34.00 and listed a Neutral rating.<\/p>\n

SiTime (SITM)<\/strong> \u2014 Rosenblatt Securities raised its price target to $900.00 from $750.00 and listed a Buy rating.<\/p>\n

Smurfit Westrock (SW)<\/strong> \u2014 Barclays lowered its price target to $55.00 from $56.00 and listed a Overweight rating.<\/p>\n

SoFi Technologies (SOFI)<\/strong> \u2014 Truist Financial raised its price target to $17.00 from $16.00 and listed a Hold rating.<\/p>\n

Sportsman’s Warehouse (SPWH)<\/strong> \u2014 LADENBURG THALM\/SH SH initiated coverage with a Buy rating and a $2.60 price target.<\/p>\n

Sportsman’s Warehouse (SPWH)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Buy rating and a $2.60 price target.<\/p>\n

Starbucks (SBUX)<\/strong> \u2014 Stephens initiated coverage with a Equal Weight rating and a $39.00 price target.<\/p>\n

Strategy (MSTR)<\/strong> \u2014 B. Riley Financial lowered its price target to $180.00 from $195.00 and listed a Buy rating.<\/p>\n

Strattec Security (STRT)<\/strong> \u2014 Freedom Broker upgraded the stock to Buy from Hold with a $79.00 price target.<\/p>\n

Strattec Security (STRT)<\/strong> \u2014 Wedbush set its price target to $79.00.<\/p>\n

Sun Communities (SUI)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Sun Communities (SUI)<\/strong> \u2014 Truist Financial lowered its price target to $129.00 from $136.00 and listed a Buy rating.<\/p>\n

Superior Group of Companies (SGC)<\/strong> \u2014 Cantor Fitzgerald reiterated its Buy rating.<\/p>\n

Syndax Pharmaceuticals (SNDX)<\/strong> \u2014 HC Wainwright lowered its price target to $36.00 from $38.00 and listed a Buy rating.<\/p>\n

Syndax Pharmaceuticals (SNDX)<\/strong> \u2014 Mizuho set its price target to $43.00.<\/p>\n

Tactile Systems Technology (TCMD)<\/strong> \u2014 BTIG Research lowered its price target to $31.00 from $35.00 and listed a Buy rating.<\/p>\n

TAT Technologies (TATT)<\/strong> \u2014 B. Riley Financial reiterated its Buy rating with a $63.00 price target.<\/p>\n

TAT Technologies (TATT)<\/strong> \u2014 UBS Group reiterated its Buy rating.<\/p>\n

TechnipFMC (FTI)<\/strong> \u2014 Piper Sandler raised its price target to $88.00 from $85.00 and listed a Overweight rating.<\/p>\n

Teledyne Technologies (TDY)<\/strong> \u2014 Morgan Stanley raised its price target to $725.00 from $715.00 and listed a Equal Weight rating.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 BTIG Research raised its price target to $100.00 from $80.00 and listed a Buy rating.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 Cantor Fitzgerald raised its price target to $92.00 from $80.00 and listed a Overweight rating.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 HC Wainwright raised its price target to $85.00 from $68.00 and listed a Buy rating.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 Jefferies upgraded the stock to Hold from Underperform with a $70 price target.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 Jefferies Financial Group upgraded the stock to Hold from Underperform with a $70.00 price target.<\/p>\n

Tempus AI (TEM)<\/strong> \u2014 Robert W. Baird raised its price target to $92.00 from $85.00 and listed a Outperform rating.<\/p>\n

Tenet Healthcare (THC)<\/strong> \u2014 KeyCorp raised its price target to $300.00 from $270.00 and listed a Overweight rating.<\/p>\n

Tenet Healthcare (THC)<\/strong> \u2014 Truist Financial reiterated its Buy rating with a $305.00 price target.<\/p>\n

Terrestrial Energy (IMSR)<\/strong> \u2014 Wedbush initiated coverage with a Neutral rating and a $4 price target.<\/p>\n

Texas Capital Bancshares (TCBI)<\/strong> \u2014 Barclays raised its price target to $110.00 from $100.00 and listed a Equal Weight rating.<\/p>\n

Textron (TXT)<\/strong> \u2014 Bank of America reiterated its Neutral rating with a $100.00 price target.<\/p>\n

The Ensign Group (ENSG)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $239.00 from $228.00 and listed a Outperform rating.<\/p>\n

Third Coast Bancshares (TCBX)<\/strong> \u2014 Keefe, Bruyette & Woods lowered its price target to $46.00 from $48.00 and listed a Market Perform rating.<\/p>\n

Toll Brothers (TOL)<\/strong> \u2014 Morgan Stanley raised its price target to $170.00 from $159.00 and listed a Overweight rating.<\/p>\n

Tower Semiconductor (TSEM)<\/strong> \u2014 DA Davidson set its price target to $335.00.<\/p>\n

Tower Semiconductor (TSEM)<\/strong> \u2014 Stifel Nicolaus lowered its price target to $235.00 from $270.00 and listed a Buy rating.<\/p>\n

Tower Semiconductor (TSEM)<\/strong> \u2014 Susquehanna lowered its price target to $305.00 from $355.00 and listed a Positive rating.<\/p>\n

Tower Semiconductor (TSEM)<\/strong> \u2014 Wedbush lowered its price target to $190.00 from $300.00 and listed a Neutral rating.<\/p>\n

Towne Bank (TOWN)<\/strong> \u2014 Keefe, Bruyette & Woods raised its price target to $39.00 from $38.00 and listed a Market Perform rating.<\/p>\n

TRex Bio, Inc. (TRXB)<\/strong> \u2014 Cantor Fitzgerald initiated coverage with a Overweight rating.<\/p>\n

TRex Bio, Inc. (TRXB)<\/strong> \u2014 JPMorgan initiated coverage with a Overweight rating and a $20 price target.<\/p>\n

TRex Bio, Inc. (TRXB)<\/strong> \u2014 Stifel initiated coverage with a Buy rating and a $39 price target.<\/p>\n

TripAdvisor (TRIP)<\/strong> \u2014 UBS Group lowered its price target to $10.00 from $12.00 and listed a Neutral rating.<\/p>\n

Trivago N.V. ADS (TRVG)<\/strong> \u2014 UBS Group lowered its price target to $4.80 from $6.00 and listed a Neutral rating.<\/p>\n

Twilio (TWLO)<\/strong> \u2014 HSBC upgraded the stock to Hold from Reduce with a $215.00 price target.<\/p>\n

Twilio (TWLO)<\/strong> \u2014 HSBC Securities upgraded the stock to Hold from Reduce with a $215 price target.<\/p>\n

Tyler Technologies (TYL)<\/strong> \u2014 The Goldman Sachs Group raised its price target to $385.00 from $345.00 and listed a Neutral rating.<\/p>\n

UMB Financial (UMBF)<\/strong> \u2014 Barclays raised its price target to $185.00 from $175.00 and listed a Overweight rating.<\/p>\n

Upstart (UPST)<\/strong> \u2014 BTIG Research lowered its price target to $40.00 from $43.00 and listed a Buy rating.<\/p>\n

Upstart (UPST)<\/strong> \u2014 Needham & Company LLC lowered its price target to $30.00 from $42.00 and listed a Buy rating.<\/p>\n

Upwork (UPWK)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

Upwork (UPWK)<\/strong> \u2014 Needham & Company LLC raised its price target to $13.00 from $11.00 and listed a Buy rating.<\/p>\n

Upwork (UPWK)<\/strong> \u2014 Royal Bank Of Canada reiterated its Sector Perform rating with a $8.00 price target.<\/p>\n

Upwork (UPWK)<\/strong> \u2014 Scotiabank raised its price target to $10.00 from $8.00 and listed a Sector Perform rating.<\/p>\n

Upwork (UPWK)<\/strong> \u2014 UBS Group raised its price target to $10.00 from $9.00 and listed a Neutral rating.<\/p>\n

V2X (VVX)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $88.00 from $81.00 and listed a Sector Perform rating.<\/p>\n

V2X (VVX)<\/strong> \u2014 Truist Financial reiterated its Hold rating with a $87.00 price target.<\/p>\n

Vale (VALE)<\/strong> \u2014 Wells Fargo & Company lowered its price target to $13.00 from $15.00 and listed a Equal Weight rating.<\/p>\n

Valley National Bancorp (VLY)<\/strong> \u2014 Barclays raised its price target to $17.00 from $15.00 and listed a Equal Weight rating.<\/p>\n

Verra Mobility (VRRM)<\/strong> \u2014 JPMorgan downgraded the stock to Underweight from Neutral.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Cantor Fitzgerald raised its price target to $619.00 from $595.00 and listed a Overweight rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 JPMorgan Chase & Co. raised its price target to $570.00 from $560.00 and listed a Overweight rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Morgan Stanley lowered its price target to $660.00 from $665.00 and listed a Overweight rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Royal Bank Of Canada raised its price target to $600.00 from $576.00 and listed a Outperform rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Scotiabank raised its price target to $660.00 from $558.00 and listed a Sector Outperform rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Stifel Nicolaus raised its price target to $563.00 from $500.00 and listed a Hold rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 TD Cowen raised its price target to $575.00 from $550.00 and listed a Buy rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 The Goldman Sachs Group raised its price target to $725.00 from $654.00 and listed a Buy rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 UBS Group raised its price target to $640.00 from $615.00 and listed a Buy rating.<\/p>\n

Vertex Pharmaceuticals (VRTX)<\/strong> \u2014 Wells Fargo & Company raised its price target to $650.00 from $550.00 and listed a Overweight rating.<\/p>\n

Victoria’s Secret & Co. (VSXY)<\/strong> \u2014 Wells Fargo & Company raised its price target to $120.00 from $100.00 and listed a Overweight rating.<\/p>\n

Viper Energy (VNOM)<\/strong> \u2014 Oppenheimer downgraded the stock to Market Perform from Outperform with a $53.00 price target.<\/p>\n

Walker & Dunlop (WD)<\/strong> \u2014 Keefe, Bruyette & Woods lowered its price target to $43.00 from $45.00 and listed a Outperform rating.<\/p>\n

Waystar (WAY)<\/strong> \u2014 Canaccord Genuity Group raised its price target to $34.00 from $33.00 and listed a Buy rating.<\/p>\n

Waystar (WAY)<\/strong> \u2014 TD Cowen lowered its price target to $39.00 from $42.00 and listed a Buy rating.<\/p>\n

Wealthfront (WLTH)<\/strong> \u2014 Wells Fargo & Company raised its price target to $12.00 from $11.50 and listed a Overweight rating.<\/p>\n

Western Alliance Bancorporation (WAL)<\/strong> \u2014 Barclays raised its price target to $95.00 from $93.00 and listed a Overweight rating.<\/p>\n

Wintrust Financial (WTFC)<\/strong> \u2014 Barclays raised its price target to $195.00 from $190.00 and listed a Overweight rating.<\/p>\n

World Kinect (WKC)<\/strong> \u2014 Morgan Stanley raised its price target to $32.00 from $30.00 and listed a Underweight rating.<\/p>\n

X-Energy (XE)<\/strong> \u2014 Wedbush initiated coverage with a Outperform rating and a $17 price target.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 KeyCorp lowered its price target to $42.00 from $48.00 and listed a Overweight rating.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Royal Bank Of Canada lowered its price target to $45.00 from $55.00 and listed a Outperform rating.<\/p>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) Analysts raised more price targets than they cut on Nov 3rd, but sentiment varied across sectors. Healthcare drew some of the…<\/p>\n","protected":false},"author":3,"featured_media":70370,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nAmerican Analyst Updates: Nov 3rd, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Updates: Nov 3rd, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Analysts raised more price targets than they cut on Nov 3rd, but sentiment varied across sectors. Healthcare drew some of the…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T19:41:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/12\/Apple-stock-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1016\" \/>\n\t<meta property=\"og:image:height\" content=\"485\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"32 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Updates: Nov 3rd, 2026\",\"datePublished\":\"2026-11-03T19:41:31+00:00\",\"dateModified\":\"2026-11-03T19:41:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\"},\"wordCount\":6604,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\",\"name\":\"American Analyst Updates: Nov 3rd, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-03T19:41:31+00:00\",\"dateModified\":\"2026-11-03T19:41:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Updates: Nov 3rd, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Updates: Nov 3rd, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Updates: Nov 3rd, 2026","og_description":"Analyst Ratings (USA) Analysts raised more price targets than they cut on Nov 3rd, but sentiment varied across sectors. Healthcare drew some of the…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-11-03T19:41:31+00:00","og_image":[{"width":1016,"height":485,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/12\/Apple-stock-1.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"32 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Updates: Nov 3rd, 2026","datePublished":"2026-11-03T19:41:31+00:00","dateModified":"2026-11-03T19:41:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/"},"wordCount":6604,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/","name":"American Analyst Updates: Nov 3rd, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-03T19:41:31+00:00","dateModified":"2026-11-03T19:41:31+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-3rd-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Updates: Nov 3rd, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=76804"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76804\/revisions"}],"predecessor-version":[{"id":76809,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76804\/revisions\/76809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/70370"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=76804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=76804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=76804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}